Affiliations: [a] Department of Surgery, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia
Correspondence:
[*]
Corresponding author: Prihantono Prihantono, Department of Surgery, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia. E-mail: prihantono.md@gmail.com
Abstract: BACKGROUND:The plasminogen urokinase activation system consists of urokinase plasminogen activator (uPA), its receptor uPAR, and plasminogen activator inhibitor type 1 (PAI-1), which are considered to have a relationship with cancer aggressiveness. Several studies have found correlations between HER2 mRNA and uPAR in disseminated tumor cells (DTCs) in breast cancer patients. They are associated with a more aggressive primary tumor phenotype and recurrence/metastasis. OBJECTIVE:This study aims to determine the relationship between the expression of urokinase-type plasminogen activator receptor (uPAR) and human epidermal growth factor receptor type 2 (HER2) with the incidence of distant metastases in breast cancer. METHODS:This study was an observational study using a cross-sectional method and was conducted at Wahidin Sudirohusodo Hospital and the network. Immunohistochemical methods carry out examination of uPAR and HER2 expression from tissues of breast cancer patients. The relationship of uPAR, HER2 expression, and metastasis was tested with the Mann Whitney test. RESULTS:The study results found that the proportion of patients with metastasis was significantly higher in high uPAR expression compared to low uPAR (77.8% compared to 36.8%). The negative HER2 expression was significantly higher in the low uPAR expression than the high uPAR (78.9% compared to 33.3%). In comparison, the positive HER2 expression was significantly higher in the high uPAR expression than the low uPAR (66.7% compared to 21.1%). In positive HER2 expression, the mean percentage of uPAR expression was significantly higher in metastases than those without metastasis (72.7% compared to 42.1%). CONCLUSIONS:uPAR expression is associated with metastasis in HER2 positive breast cancer.
Keywords: Breast cancer, urokinase-type plasminogen activator, uPAR, HER2, metastasis
DOI: 10.3233/BD-219001
Journal: Breast Disease, vol. 40, no. s1, pp. S1-S7, 2021
